PL2846791T3 - HPN-100 do zastosowania do leczenia zaburzeń retencji azotu - Google Patents
HPN-100 do zastosowania do leczenia zaburzeń retencji azotuInfo
- Publication number
- PL2846791T3 PL2846791T3 PL12874745T PL12874745T PL2846791T3 PL 2846791 T3 PL2846791 T3 PL 2846791T3 PL 12874745 T PL12874745 T PL 12874745T PL 12874745 T PL12874745 T PL 12874745T PL 2846791 T3 PL2846791 T3 PL 2846791T3
- Authority
- PL
- Poland
- Prior art keywords
- hpn
- treatment
- nitrogen retention
- retention disorders
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636256P | 2012-04-20 | 2012-04-20 | |
| EP12874745.8A EP2846791B1 (en) | 2012-04-20 | 2012-09-11 | Hpn-100 for use in the treatment of nitrogen retention disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2846791T3 true PL2846791T3 (pl) | 2017-07-31 |
Family
ID=49380684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12874745T PL2846791T3 (pl) | 2012-04-20 | 2012-09-11 | HPN-100 do zastosowania do leczenia zaburzeń retencji azotu |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US9561197B2 (enExample) |
| EP (2) | EP2846791B1 (enExample) |
| JP (3) | JP6234436B2 (enExample) |
| KR (2) | KR20150013170A (enExample) |
| CN (3) | CN111991383A (enExample) |
| AU (3) | AU2012377389A1 (enExample) |
| BR (1) | BR112014026138A2 (enExample) |
| CL (2) | CL2014002807A1 (enExample) |
| CY (1) | CY1118838T1 (enExample) |
| DK (1) | DK2846791T3 (enExample) |
| EC (1) | ECSP14024561A (enExample) |
| ES (2) | ES2807951T3 (enExample) |
| HR (1) | HRP20170651T1 (enExample) |
| HU (1) | HUE032726T2 (enExample) |
| IL (2) | IL235127A (enExample) |
| LT (1) | LT2846791T (enExample) |
| MX (1) | MX365302B (enExample) |
| PL (1) | PL2846791T3 (enExample) |
| PT (1) | PT2846791T (enExample) |
| RS (1) | RS55870B1 (enExample) |
| SG (2) | SG11201406745VA (enExample) |
| SI (1) | SI2846791T1 (enExample) |
| SM (1) | SMT201700219T1 (enExample) |
| WO (1) | WO2013158145A1 (enExample) |
| ZA (1) | ZA201407597B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012316750B2 (en) | 2011-09-30 | 2017-08-31 | Immedica Pharma Ab | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| CN111991383A (zh) * | 2012-04-20 | 2020-11-27 | 伊梅尔迪卡制药公司 | 苯乙酸前药的治疗性监测方法 |
| HK1210699A1 (en) * | 2012-11-21 | 2016-05-06 | Horizon Therapeutics, Inc. | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
| HRP20191710T1 (hr) | 2013-10-14 | 2019-12-13 | Immedica Pharma Ab | Postupci za liječenje poremećaja ciklusa uree |
| WO2015187641A1 (en) * | 2014-06-04 | 2015-12-10 | Horizon Therapeutics, Inc. | Methods for treating urea cycle disorders to prevent hyperammonemic crises by controlling blood ammonia levels |
| US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
| US20190076383A1 (en) * | 2017-09-08 | 2019-03-14 | Horizon Therapeutics, Llc | Methods for treating urea cycle disorders |
| US10668040B2 (en) * | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| US5635532A (en) | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
| US5879657A (en) | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
| CA2212047C (en) | 1995-02-07 | 2010-11-16 | Saul W. Brusilow | Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders |
| US6219567B1 (en) | 1999-06-21 | 2001-04-17 | Cardiox Corporation | Monitoring of total ammoniacal concentration in blood |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| US20050273359A1 (en) | 2004-06-03 | 2005-12-08 | Young David E | System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure |
| ES2341120T3 (es) | 2004-11-26 | 2010-06-15 | Ucl Business Plc | Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatia hepatica. |
| US20060135612A1 (en) | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| US20070004805A1 (en) | 2005-07-01 | 2007-01-04 | Navinta Llc | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
| WO2007059031A2 (en) | 2005-11-10 | 2007-05-24 | Massachusetts Institute Of Technology | Methods and compositions for raising levels and release of gamma aminobutyric acid |
| US8094521B2 (en) | 2007-02-28 | 2012-01-10 | Nightingale Products LLC | Caregiver personal alert device |
| GB2451259B (en) * | 2007-07-25 | 2011-07-20 | Gp Acoustics | Loudspeaker |
| JP5468015B2 (ja) | 2008-01-08 | 2014-04-09 | アクセリア ファーマシューティカルズ | 抗菌ペプチド系に対する作動薬 |
| PL3133396T3 (pl) | 2008-04-29 | 2019-03-29 | Horizon Therapeutics, Llc | Sposób leczenia z zastosowaniem leków wychwytujących amoniak |
| WO2010025303A1 (en) | 2008-08-29 | 2010-03-04 | Hyperion Therapeutics | Dosing and monitoring patients on nitrogen-scavenging drugs |
| TR201816616T4 (tr) * | 2008-08-29 | 2018-11-21 | Horizon Therapeutics Llc | Amonyak temizleyici ilaçlar kullanılan tedavi metotları. |
| CN102482713B (zh) * | 2009-05-11 | 2017-06-30 | 博格有限责任公司 | 利用表观代谢转变剂、多维细胞内分子或环境影响剂诊断肿瘤障碍的方法 |
| PT2456304E (pt) | 2009-07-24 | 2015-10-12 | Baylor College Medicine | Métodos de modulação de ácidos de cadeia ramificada e utilização dos mesmos |
| WO2012028620A1 (en) | 2010-08-31 | 2012-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation |
| AU2012316750B2 (en) | 2011-09-30 | 2017-08-31 | Immedica Pharma Ab | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| CN111991383A (zh) | 2012-04-20 | 2020-11-27 | 伊梅尔迪卡制药公司 | 苯乙酸前药的治疗性监测方法 |
| HK1210699A1 (en) | 2012-11-21 | 2016-05-06 | Horizon Therapeutics, Inc. | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
-
2012
- 2012-09-11 CN CN202010449455.7A patent/CN111991383A/zh active Pending
- 2012-09-11 HR HRP20170651TT patent/HRP20170651T1/hr unknown
- 2012-09-11 HU HUE12874745A patent/HUE032726T2/en unknown
- 2012-09-11 DK DK12874745.8T patent/DK2846791T3/en active
- 2012-09-11 EP EP12874745.8A patent/EP2846791B1/en active Active
- 2012-09-11 ES ES17154858T patent/ES2807951T3/es active Active
- 2012-09-11 PL PL12874745T patent/PL2846791T3/pl unknown
- 2012-09-11 CN CN201280074143.6A patent/CN104540507A/zh active Pending
- 2012-09-11 EP EP17154858.9A patent/EP3222275B1/en active Active
- 2012-09-11 MX MX2014012694A patent/MX365302B/es active IP Right Grant
- 2012-09-11 CN CN202111191403.5A patent/CN113995743A/zh active Pending
- 2012-09-11 LT LTEP12874745.8T patent/LT2846791T/lt unknown
- 2012-09-11 ES ES12874745.8T patent/ES2623470T3/es active Active
- 2012-09-11 SM SM20170219T patent/SMT201700219T1/it unknown
- 2012-09-11 AU AU2012377389A patent/AU2012377389A1/en not_active Abandoned
- 2012-09-11 WO PCT/US2012/054673 patent/WO2013158145A1/en not_active Ceased
- 2012-09-11 SI SI201230933A patent/SI2846791T1/sl unknown
- 2012-09-11 KR KR1020147032114A patent/KR20150013170A/ko not_active Withdrawn
- 2012-09-11 SG SG11201406745VA patent/SG11201406745VA/en unknown
- 2012-09-11 BR BR112014026138A patent/BR112014026138A2/pt not_active Application Discontinuation
- 2012-09-11 JP JP2015506953A patent/JP6234436B2/ja active Active
- 2012-09-11 RS RS20170421A patent/RS55870B1/sr unknown
- 2012-09-11 PT PT128747458T patent/PT2846791T/pt unknown
- 2012-09-11 KR KR1020197029026A patent/KR102264579B1/ko active Active
- 2012-09-11 SG SG10201608749UA patent/SG10201608749UA/en unknown
- 2012-09-11 US US13/610,580 patent/US9561197B2/en active Active
-
2014
- 2014-10-17 CL CL2014002807A patent/CL2014002807A1/es unknown
- 2014-10-19 IL IL235127A patent/IL235127A/en active IP Right Grant
- 2014-10-20 ZA ZA2014/07597A patent/ZA201407597B/en unknown
- 2014-10-27 EC ECIEPI201424561A patent/ECSP14024561A/es unknown
-
2017
- 2017-01-10 US US15/402,780 patent/US20170266143A1/en not_active Abandoned
- 2017-04-20 CY CY20171100449T patent/CY1118838T1/el unknown
- 2017-05-30 CL CL2017001375A patent/CL2017001375A1/es unknown
- 2017-08-25 US US15/687,136 patent/US20180015058A1/en not_active Abandoned
- 2017-10-24 JP JP2017204831A patent/JP6637941B2/ja active Active
- 2017-11-26 IL IL255918A patent/IL255918B/en active IP Right Grant
-
2018
- 2018-01-09 AU AU2018200163A patent/AU2018200163B2/en active Active
- 2018-05-15 US US15/980,431 patent/US20180263938A1/en not_active Abandoned
-
2019
- 2019-03-15 AU AU2019201811A patent/AU2019201811B2/en active Active
- 2019-08-19 JP JP2019149843A patent/JP2019219413A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285843A (en) | Ibrutinib for use in the treatment of chronic graft versus host disease | |
| PL3542798T3 (pl) | Aceklidyna do zastosowania w leczeniu starczowzroczności | |
| DK2938740T3 (da) | Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser | |
| DK2836200T3 (da) | Termoreversible hydrogelpræparater til anvendelse i behandlingen af lidelser i urothelium | |
| PT2919796T (pt) | Utilização de akkermansia para o tratamento de distúrbios metabólicos | |
| PT3811943T (pt) | Composto para uso no tratamento de distúrbios oculares | |
| IL239355A0 (en) | Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders | |
| PL2544682T3 (pl) | Fitokannabinoidy w leczeniu glejaka | |
| HRP20181227T1 (hr) | Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r | |
| LT2961410T (lt) | Pirazolopirimidino darinių naudojimas gydant su pi3k susijusius sutrikimus | |
| DK2815769T3 (da) | Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet | |
| PL2838539T3 (pl) | Składniki estrogenowe do zastosowania w leczeniu zaburzeń neurologicznych | |
| PL2830654T3 (pl) | Sposoby i kompozycje do leczenia zapalenia | |
| DK2827813T3 (da) | Kuldebehandlingsindretning | |
| LT2928477T (lt) | Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui | |
| IL238027A0 (en) | 2-phenyl-5-heterocyclyl-tetrahydro-h2-pyran-3-amine compounds for use in the treatment of diabetes and related disorders | |
| IL235127A (en) | Hpn-100 for use in the treatment of nitrogen-related diseases | |
| EP2922536A4 (en) | USE OF BUCILLAMINE IN THE TREATMENT OF GOUTTE | |
| DK2830645T3 (da) | Neuregulin til anvendelse i behandling af perifær nervelæsion | |
| IL227747A0 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| HRP20181554T1 (hr) | Tauroursodezoksikolna kiselina (tudca), namijenjena upotrebi u liječenju neurodegenerativnih poremećaja | |
| PL2988750T5 (pl) | Zastosowanie chlorowodorku landilolu w długotrwałym leczeniu tachyarytmii | |
| ITRM20120530A1 (it) | Compounds for use in the treatment of parasitic diseases | |
| PL2861568T3 (pl) | Aminy trzeciorzędowe do zastosowania w leczeniu zaburzeń serca | |
| SI2872176T1 (sl) | Karboranilporfirin za uporabo pri zdravljenju raka |